Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic Lymphocytic Leukemia

DHMEQ, a new NF-κB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells

Abstract

Chronic lymphocytic leukemia (CLL) is a low-grade lymphoid malignancy incurable with conventional modalities of chemotherapy. Strong and constitutive nuclear factor kappa B (NF-κB) activation is a characteristic of CLL cells. We examined the effects of a new NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on CLL cells. Dehydroxymethylepoxyquinomicin completely abrogated constitutive NF-κB activity and induced apoptosis of CLL cells. Apoptosis induced by DHMEQ was accompanied by downregulation of NF-κB-dependent antiapoptotic genes: c-IAP, Bfl-1, Bcl-XL and c-FLIP. Dehydroxymethylepoxyquinomicin also inhibited NF-κB induced by CD40 and enhanced fludarabine-mediated apoptosis of CLL cells. Results of this study suggest that inhibition of constitutive and inducible NF-κB by DHMEQ in combination with fludarabine is a promising strategy for the treatment of CLL.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. Keating MJ . Chronic lymphocytic leukemia. Semin Oncol 1999; 26: 107–114.

    CAS  PubMed  Google Scholar 

  2. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–3389.

    CAS  PubMed  Google Scholar 

  3. Griffin J . The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 2001; 28: 3–8.

    CAS  Article  PubMed  Google Scholar 

  4. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572.

    CAS  PubMed  Google Scholar 

  5. Capdeville R, Silberman S, Dimitrijevic S . Imatinib: the first 3 years. Eur J Cancer 2002; 38 (Suppl 5): S77–S82.

    Article  PubMed  Google Scholar 

  6. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ . Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200–2206.

    CAS  Article  PubMed  Google Scholar 

  7. Barkett M, Gilmore TD . Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6910–6924.

    CAS  Article  PubMed  Google Scholar 

  8. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS . NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785–5799.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003; 9: 4570–4577.

    CAS  PubMed  Google Scholar 

  10. Kelley TW, Alkan S, Srkalovic G, Hsi ED . Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res 2004; 28: 845–850.

    CAS  Article  PubMed  Google Scholar 

  11. Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000; 10: 865–869.

    CAS  Article  PubMed  Google Scholar 

  12. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K . Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002; 277: 24625–24630.

    CAS  Article  PubMed  Google Scholar 

  13. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  PubMed  Google Scholar 

  14. Andrews NC, Faller DV . A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991; 19: 2499.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin–Reed–Sternberg cells. Oncogene 2002; 21: 2493–2503.

    CAS  Article  PubMed  Google Scholar 

  16. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92: 990–995.

    CAS  PubMed  Google Scholar 

  17. Carew JS, Nawrocki ST, Krupnik YV, Dunner Jr K, McConkey DJ, Keating MJ et al. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 2006; 107: 222–231.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM . High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 2005; 113: 730–737.

    CAS  Article  PubMed  Google Scholar 

  19. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004; 18: 1391–1400.

    CAS  Article  PubMed  Google Scholar 

  20. Tallman MS, Hakimian D . Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463–2474.

    CAS  PubMed  Google Scholar 

  21. Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W . Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 2000; 14: 1405–1413.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Professor Marshall E Kadin, Harvard Medical School, for critical comments on the manuscript. This work was supported in part by Grants-in-Aid for Scientific Research from Japanese Society for Promotion of Science and Integrative Research Program of the Graduate School of Medical Sciences, Kitasato University to R Horie.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R Horie.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Horie, R., Watanabe, M., Okamura, T. et al. DHMEQ, a new NF-κB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20, 800–806 (2006). https://doi.org/10.1038/sj.leu.2404167

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404167

Keywords

  • CLL
  • NF-κB
  • apoptosis
  • DHMEQ
  • fludarabine

Further reading

Search

Quick links